Intra-Cellular Therapies (NASDAQ:ITCI) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a research note published on Thursday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also weighed in on ITCI. Morgan Stanley raised their price objective on Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Needham & Company LLC reissued a “hold” rating and set a $100.00 price target on shares of Intra-Cellular Therapies in a research report on Monday, January 13th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Finally, Baird R W downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $102.15.

Intra-Cellular Therapies Trading Down 0.1 %

Shares of ITCI stock opened at $127.07 on Thursday. The firm has a fifty day simple moving average of $91.53 and a 200-day simple moving average of $82.02. The company has a market capitalization of $13.47 billion, a PE ratio of -146.06 and a beta of 0.70. Intra-Cellular Therapies has a twelve month low of $62.78 and a twelve month high of $128.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The firm had revenue of $175.40 million during the quarter, compared to analysts’ expectations of $172.30 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business’s quarterly revenue was up 39.0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.25) earnings per share. Equities research analysts predict that Intra-Cellular Therapies will post -0.64 EPS for the current year.

Insider Activity

In other news, President Michael Halstead sold 22,869 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total transaction of $2,038,085.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Sharon Mates sold 51,000 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. This trade represents a 4.55 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Intra-Cellular Therapies

A number of hedge funds have recently made changes to their positions in the business. R Squared Ltd bought a new position in Intra-Cellular Therapies in the 4th quarter worth approximately $205,000. KBC Group NV boosted its position in Intra-Cellular Therapies by 31.8% during the 4th quarter. KBC Group NV now owns 3,774 shares of the biopharmaceutical company’s stock worth $315,000 after acquiring an additional 910 shares during the period. SG Americas Securities LLC grew its stake in shares of Intra-Cellular Therapies by 204.4% in the fourth quarter. SG Americas Securities LLC now owns 12,917 shares of the biopharmaceutical company’s stock worth $1,079,000 after purchasing an additional 8,673 shares in the last quarter. Cetera Trust Company N.A increased its holdings in shares of Intra-Cellular Therapies by 17.3% during the fourth quarter. Cetera Trust Company N.A now owns 2,955 shares of the biopharmaceutical company’s stock valued at $247,000 after purchasing an additional 435 shares during the period. Finally, Barlow Wealth Partners Inc. bought a new stake in shares of Intra-Cellular Therapies during the fourth quarter valued at about $184,000. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.